Biologics dominate treatment costs for Crohn’s and ulcerative colitis

Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)

Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.

Prevalence of Crohn’s Disease (CD) and Ulcerative Colitis (UC), Biologic Therapy Use, and Total Medical and Pharmacy Claims Expense Associated with CD and UC in a Population of 15 Million Commercially Insured Members (Spring 2019)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Biologics dominate treatment costs for Crohn’s and ulcerative colitis

Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)

Prevalence of Crohn’s Disease (CD) and Ulcerative Colitis (UC), Biologic Therapy Use, and Total Medical and Pharmacy Claims Expense Associated with CD and UC in a Population of 15 Million Commercially Insured Members (Spring 2019)

About Prime Therapeutics

Related news

Clinical News: April 2024

Drug Approvals Monthly Update: April 2024

Drug Approvals Quarterly Update: April 2024